US4994440A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for the treatment of renal cell carcinoma
Assignee: Novartis Corp
•
Filing: 1989-02-13
•
Granted: 1991-02-19
•
Expires: 2009-02-13
Abstract
Abstract The present invention relates to a method for the treatment of renal cell carcinoma comprising administering to a warm blooded mammal in need thereof a therapeutically effective amount of N-acetylmuramyl-L-alanyl-D-isogutamin-yl-L-alanine-2-(1,2-dipalmitoyl-sn-glyc ro-3-hydroxyphosphoryloxy)ethylamide monosodium salt preferably encapsulated in a multilamellar liposomal composition comprising phosphatidylcholine and phosphatidylserine.
Inventors
- 👤 Patrick J. Creaven
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 18:15
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K9/1271; A61K38/00; A61K38/04; A61K38/14
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
27 words
A method for the treatment of renal cell carcinoma comprising administering to a warm blooded mammal in need thereof a therapeutically effective amount of N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-di-palmitoyl-sn-glycero-3-hydroxyphosphoryloxy)ethylamide monosodium salt.
Claim 2
Independent Claim
27 words
A method for the treatment of renal cell carcinoma comprising administering to a warm blooded mammal in need thereof a therapeutically effective amount of N-acetyl-muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-di-palmitoyl-sn-glycero-3-hydroxyphosphoryloxy)ethylamide monosodium salt.
Claim 3
Dependent Claim
29 words
A method according to claim 1 wherein said N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-L-(1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)ethylamide monosodium salt is encapsulated in a multilamellar liposome comprising synthetic phosphatidylcholine and synthetic phosphatidylserine in a molar ratio of 7:3.
Claim 4
Dependent Claim
30 words
A method according to claim 1 wherein said N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)ethylamide monosodium salt is administered in an amount of about 0.01 mg/m 2 to about 4 mg/m 2 once or twice weekly.
Claim 5
Dependent Claim
15 words
A method according to claim 1 wherein said N-acetyl muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2-di-palmitoyl-sn-glycero-3-hydroxyphosphoryloxy)ethylamide monosodium salt is intravenously infused.
Claim 6
Dependent Claim
12 words
A method according to claim 1 wherein said mammal is a human.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-02-18 | 1994-08-20 | 1995-02-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-02-18 | 1998-08-20 | 1999-02-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-02-18 | 2002-08-20 | 2003-02-19 | $7700.00 | Window Closed / Lapsed |